“…9,10 , Pseudomonas aeruginosa 7,9,10,31 , Enterobacter spp. 9,10,16,18,23,24,28 , Haemophilus spp. 7,10,15,17,18,23,27,31 and Acinetobacter baumannii 12,14,15,17,22 ; however this information was often not reported, especially in literature identified in the initial review (Table 2 and Table 3).…”
The coronavirus disease 2019 (COVID-19) pandemic has had severe implications on healthcare systems and the patients affected by this infectious disease. To improve outcomes for patients with COVID-19 and limit future antimicrobial resistance, there is continued urgency to improve our understanding of the rates and causative agents of secondary bacterial infections in patients with COVID‑19, and recognise whether antibiotics are being overused in patients prior to and following COVID-19 diagnosis. This article presents the results of a rapid review comparing reported rates of secondary bacterial infections with rates of antibiotic use in patients with COVID-19 predominantly in a hospital setting, within the context of treatment guidelines and recommendations. The review revealed rates of antibiotic use in patients with COVID-19 of 37–100%, far outweighing rates of secondary bacterial infections which were typically below 20%. There was a lack of consistent reporting of causative microorganisms of secondary infections, and the distinction between bacterially- and virally-induced sepsis was rarely made. Early in the pandemic, healthcare agencies published treatment guidelines recognising the importance of antimicrobial stewardship. However, many are yet to provide updated guidance detailing the most appropriate antibiotics to treat patients with concurrent COVID-19 and secondary bacterial infections in a way which limits the emergence of drug-resistant infections and does not negatively impact patient outcomes. Without significant improvements to the testing and reporting of causative organisms and corresponding updates to antimicrobial treatment guidelines, there is a risk of worsened clinical outcomes and increased burden on healthcare systems from antimicrobial resistance during the remainder of the COVID-19 pandemic and beyond.
“…9,10 , Pseudomonas aeruginosa 7,9,10,31 , Enterobacter spp. 9,10,16,18,23,24,28 , Haemophilus spp. 7,10,15,17,18,23,27,31 and Acinetobacter baumannii 12,14,15,17,22 ; however this information was often not reported, especially in literature identified in the initial review (Table 2 and Table 3).…”
The coronavirus disease 2019 (COVID-19) pandemic has had severe implications on healthcare systems and the patients affected by this infectious disease. To improve outcomes for patients with COVID-19 and limit future antimicrobial resistance, there is continued urgency to improve our understanding of the rates and causative agents of secondary bacterial infections in patients with COVID‑19, and recognise whether antibiotics are being overused in patients prior to and following COVID-19 diagnosis. This article presents the results of a rapid review comparing reported rates of secondary bacterial infections with rates of antibiotic use in patients with COVID-19 predominantly in a hospital setting, within the context of treatment guidelines and recommendations. The review revealed rates of antibiotic use in patients with COVID-19 of 37–100%, far outweighing rates of secondary bacterial infections which were typically below 20%. There was a lack of consistent reporting of causative microorganisms of secondary infections, and the distinction between bacterially- and virally-induced sepsis was rarely made. Early in the pandemic, healthcare agencies published treatment guidelines recognising the importance of antimicrobial stewardship. However, many are yet to provide updated guidance detailing the most appropriate antibiotics to treat patients with concurrent COVID-19 and secondary bacterial infections in a way which limits the emergence of drug-resistant infections and does not negatively impact patient outcomes. Without significant improvements to the testing and reporting of causative organisms and corresponding updates to antimicrobial treatment guidelines, there is a risk of worsened clinical outcomes and increased burden on healthcare systems from antimicrobial resistance during the remainder of the COVID-19 pandemic and beyond.
“…Bradley J Langford, BScPhm, PharmD 1,2 Miranda So, BScPhm, PharmD, MPH 3,4,5 Valerie Leung, BScPhm, MBA 1,6 Sumit Raybardhan, BScPhm, MPH 7 Jennifer Lo, BScPhm, PharmD 8 Tiffany Kan, BScPhm, PharmD 6 Felicia Leung, HBSc 4 Nick Daneman, MD, MSc 1,4,8,10,11 Derek R MacFadden, MD, ScD 12 Jean-Paul R Soucy, MSc 9…”
Section: 'Predictors and Microbiology Of Respiratory And Bloodstream ...mentioning
confidence: 99%
“…Our exclusion of letters to the editor was meant to remove any commentary or narrative -type correspondence. However, we did include research letters that provided sufficient data to meet inclusion criteria [5,6].…”
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and metaregression Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2021.11.008. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.